Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study
by
, , ,
Hideyuki Shiba
1,†,
Takuya Kotani
1,*,†,
Koji Nagai
1,
Kenichiro Hata
1,
Wataru Yamamoto
2,
Ayaka Yoshikawa
1,
Yumiko Wada
1,
Yuri Hiramatsu
1,
Hidehiko Makino
1,
Yo Ueda
3,
Akira Onishi
4,
Koichi Murata
4,
Hideki Amuro
5,
Yonsu Son
5,
Ryota Hara
6,
Toru Hirano
7,
Kosuke Ebina
8,
Masaki Katayama
9,
Motomu Hashimoto
10 and
Tohru Takeuchi
1 1
Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan
2
Department of Health Information Management, Kurashiki Sweet Hospital, Okayama 710-0016, Japan
3
Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
4
Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan
5
First Department of Internal Medicine, Kansai Medical University, Osaka 573-1191, Japan
6
Rheumatology Clinic and Department of Orthopaedic Surgery, Nara Medical University, Nara 634-8521, Japan
7
Department of Rheumatology, Nishinomiya Municipal Central Hospital, Nishinomiya 663-8014, Japan
8
Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
9
Department of Rheumatology, Osaka Red Cross Hospital, Osaka 543-0027, Japan
10
Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this study.
Int. J. Mol. Sci. 2023, 24(8), 7399; https://doi.org/10.3390/ijms24087399
Submission received: 28 February 2023
/
Revised: 11 April 2023
/
Accepted: 14 April 2023
/
Published: 17 April 2023
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Abstract
:This multicenter retrospective study aimed to clarify the prognostic factors for mortality and changes in treatment modalities and disease activities after the onset of Pneumocystis jirovecii pneumonia (PCP) in patients with rheumatoid arthritis (RA). Data regarding the clinical background, treatment modalities, and disease activity indicators of RA at the onset of PCP (baseline), and 6 months and 12 months after treatment were extracted. Of the 37 patients with RA-PCP (median age, 69 years; 73% female), chemical prophylaxis was administered to 8.1%. Six patients died during PCP treatment. The serum C-reactive protein (CRP) levels and the prednisolone (PDN) dose at baseline in the PCP death group were significantly higher than those in the survivor group. Multivariate analysis using a Cox regression model showed that PDN dose at baseline was a predictor of death from PCP in patients with RA. During the 12 months from baseline, the RA disease activity significantly decreased. A high dose of corticosteroids for RA may result in a poor prognosis when PCP is complicated. In the future, preventive administration techniques must be established for patients with RA who need PCP prevention.
1. Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and destruction [1]. Patients with RA frequently develop opportunistic infections during their clinical course, including respiratory infections, which result in a poor prognosis [2,3,4].
Pneumocystis jirovecii (PC) is a fungal pathogen that causes pneumonia in infancy and in compromised hosts with decreased cell-mediated immunity [5,6]. The use of corticosteroids and immunosuppressants is a risk factor for PC pneumonia (PCP), and patients who develop PCP often have a fatal course [5,7]. In patients with RA, corticosteroids and immunosuppressants, including methotrexate, are used. In addition, the use of biological disease-modifying anti-rheumatic drugs (DMARDs) and targeted synthetic DMARDs (tsDMARDs) causes patients to become immunocompromised, and this is a risk for PCP comorbidity [8,9].
Risk factors for developing PCP in patients with RA include older age, male sex, corticosteroid use, and pulmonary lesions [10]. However, poor prognostic factors for mortality, changes in treatment modalities for RA, and changes in the disease activity of RA after the onset of PCP are still unclear. Therefore, we extracted the clinical background of the patients, the disease activities of RA, and the treatment modalities for RA at the onset of PCP (baseline) and examined the poor prognostic factors of mortality. In addition, we also examined changes in the treatment modalities and in the disease activities of RA during the 12 months after the baseline. The aim of the present study is to clarify the prognostic factors of mortality in RA patients with PCP and the changes in RA disease activity and treatment modalities for RA after the onset of PCP.
2. Results
2.1. Characteristics of the Patients
The study population was selected from all patients with RA-complicated PCP (RA-PCP) in the ANSWER cohort (n = 37) who fulfilled the inclusion criteria. The baseline characteristics of the participants are shown in Table 1. The median age was 69.0 (63–75) years, the disease duration was 10.7 (2.77–20.4) years, and 73.0% of the patients were women. In the treatment modalities for RA, methotrexate (MTX) and prednisolone (PDN) were used in 86.5% and 67.6% of patients, respectively, and the doses were 7.0 (4.0–9.5) mg/week and 4.0 (0–9.0) mg/day, respectively. The comorbidity rates of diabetes mellitus, interstitial lung disease, lung emphysema, bronchiectasis, latent tuberculosis infection (LTBI), and lung nontuberculous mycobacterial (NTM) infection were 21.6%, 29.7%, 10.8%, 8.11%, 5.41%, and 2.70%, respectively.
As a chemical prophylaxis, atovaquone was administered to 8.1% of patients. No patient was administered sulfamethoxazole-trimethoprim (SMX/TMP) mixture.
2.2. Treatments for PCP
The treatment details and outcomes of patients with PCP are presented in Table 2. A TMP/SMX mixture was used in 94.6% of the patients, and the initial dose was 9 (9–12) mg/day. One g of TMP/SMX mixture contains 80 mg of TMP and 400 mg of SMX. Pentamidine inhalation, atovaquone, methylprednisolone pulse therapy, and oral prednisolone were used in 32.4%, 13.5%, 32.4%, and 94.3% of patients, respectively. The initial prednisolone dose was 64 (40–80) mg/day.
2.3. Comparison of the Baseline Clinical Characteristics and Treatment Regimens of Patients Who Died from PCP and Survivors
During the 12-month follow-up period, 6 patients died due to PCP, and the duration between baseline and death was 13 (6.5–24.3) days. We compared the baseline clinical characteristics and treatment regimens of the 6 patients in the PCP death group and the 31 in the survivor group (Table 3). There was no difference between the PCP death and survivor groups in terms of age, sex, disease duration of RA, disease activity indicators, or complications. Although the serum CRP levels of 15.9 (6.98–18.6) mg/dL in the PCP death group were significantly higher than those in the survivor group of 5.7 (1.85–9.56) mg/dL (p = 0.035), other laboratory findings did not differ between the two groups. The PDN dose of 9.0 (5.75–19.4) mg/day in the PCP death group was significantly higher than that in the survivor group of 3.0 (0–5.0) mg/day (p = 0.006), but other treatment modalities for RA did not differ between the two groups.
We also compared the baseline respiratory conditions, including duration of respiratory symptoms and PaO2/FiO2 ratio, between the PCP death group and the survival group. The duration of respiratory symptoms could be extracted for 14 (9–39) days in 3 PCP deaths and 7 (4–13) days in 23 survivors, and the PaO2/FiO2 ratio could be extracted for 64.6 (46.7–251.9) in all PCP deaths and 238.1 (188.8–344.2) in 21 survivors. Although there was no difference in the duration of respiratory symptoms between the two groups, the PaO2/FiO2 ratio was significantly lower in the PCP death group compared with the survival group.
2.4. Cox Regression Analyses of Death from PCP in Patients with RA
Serum CRP levels and PDN dose at baseline were identified as risk factors for death from PCP. To confirm these findings, we performed univariate and multivariate analyses using a Cox proportional hazards model (Table 4). Age was considered a potential confounder and adjusted as a covariate. Univariate analysis using a Cox regression model showed that the PDN dose at baseline was a predictor of death from PCP in patients with RA (p = 0.003). Multivariate analysis also showed that PDN dose at baseline was a predictor of death from PCP in patients with RA (p = 0.003).
2.5. Changes in Treatment Modalities for RA and Chemical Prophylaxis for PCP during the Course after PCP Treatment
Table 5 shows the comparisons of treatment modalities for RA and chemical prophylaxis modalities for PCP at baseline, and at 6 and 12 months after. The usage rate and dose of MTX were significantly lower at 6 months after and at 12 months after baseline than those at baseline. The usage rate of PDN significantly increased at 6 months after baseline compared with that at baseline, and the dose of PDN significantly decreased at 12 months after baseline compared with that at 6 months after baseline. The usage rate of bDMARDs/tsDMARDs was significantly lower at 6 months after baseline than that at baseline. The usage rate and the dose of SMX/TMP were significantly higher at 6 months after and 12 months after, compared with those at baseline.
2.6. Changes in Disease Activities of RA during the Course after PCP Treatment
Table 6 shows the changes in RA disease activity during the course of PCP treatment. During the 6-month period from baseline, DAS28CRP and serum CRP levels significantly decreased (p = 0.046 and <0.001, respectively). During the 12-month period from baseline, DAS28-CRP, SDAI, and serum CRP levels significantly decreased (p = 0.001, 0.012, and <0.001, respectively). There was no significant change in RA disease activity between 6 and 12 months.
3. Discussion
Risk factors for PCP complications in patients with RA have been reported to be older age, male sex, existing lung lesions, and the use of corticosteroids, MTX, and bDMARDs [8,11]. In Japanese patients with RA during IFX treatment, age 65 years or older, PDN use of 6 mg/day or more, and existing lung lesions were reported as risk factors for PCP complications [11]. In Japanese patients with RA during ETN treatment, age 65 years and older, existing lung lesions, and the use of MTX have also been reported as risk factors for PCP complications [12]. In the present study, the median age of the patients was 69 years, and the complication rate of lung lesions was high. In addition, the usage rates of PDN, MTX, and bDMARDs/tsDMARDs were also high at 67.6%, 86.5%, and 37.8%, respectively, which supports the results of previous reports. A previous study reported that the median serum levels of IgG were significantly lower in patients with RA-PCP during IFX treatment (1192 mg/dL) than in patients with RA without PCP (1540 mg/dL) [13]. In the present study, the median serum IgG levels also decreased to 948 mg/dL.
Pentamidine inhalation, atovaquone, and TMP/SMX have been used to prevent PCP. The need for prophylaxis against PCP has been advocated receiving immunosuppressive drugs in addition to prednisolone 20 mg/day or higher [14]. However, there are no established guidelines for specific indications, drug selection and dosage, or administration period for PCP prevention in patients with RA. Although TMP/SMX is effective in preventing PCP, its administration is recommended when the risk of developing PCP exceeds 3% from the viewpoint of side effects [8]. Moreover, the complication rate of PCP in patients with RA using bDMARDs is as low as 0.2–0.4% [15,16,17,18,19], and it does not reach the standard for TMP/SMX use. Therefore, it is necessary to further select cases for which prophylactic administration of TMP/SMX is indicated according to the risk factors of the patient’s background. Although, in the present study, any of the risk factors for PCP complications—65 years or older, PDN doses of 6 mg/day or higher, MTX use, bDMARDs/tsDMARDs use, or existing lung lesions—were present in all patients, PCP prophylaxis by atovaquone was performed in only three patients. This suggests that, in the real world, sufficient PCP prophylaxis may not be administered to patients with RA. While considering the side effects of PCP preventive drugs, it is also necessary to pay attention to the risk factors for PCP complications. Of 107 Japanese CTD patients receiving high-dose corticosteroids who were prophylactically treated with atovaquone, 5 were reported to have complicated PCP [20]. Although the frequency may be low, it is also considered necessary to pay attention to the possibility of complication with PCP even during prophylactic administration of atovaquone in patients with RA under immunosuppressive therapy.
Existing lung lesions have been reported to affect the mortality and prognosis of patients with RA-PCP [11,12]. Although there was no difference in the complication rate of existing lung lesions between the death and the survivor groups in the present study, existing lung lesions may have affected the deterioration of respiratory status due to PCP. Poor prognostic factors for mortality in patients with RA-PCP have not yet been clarified. In the present study, high-dose corticosteroids at baseline were independently associated with PCP mortality. These results suggest that the prognosis may be poor in cases of severe immunosuppression in RA-PCP. Even with diseases other than RA, it has been reported that long-term or high-dose corticosteroid use is associated with the risk of developing PCP in patients with asthma, COPD patients with lung cancer, and patients with COVID-19 infection [21,22,23,24,25,26]. It is suggested that reducing the amount and duration of corticosteroid use may reduce the complication rate of PCP and improve prognosis.
In the present study, the MTX concomitant rate/dose decreased, and the PDN concomitant rate increased 6 months after the onset of PCP. Owing to excessive immunosuppression and the risk of drug-induced pneumonia, the use of MTX might be avoided after the onset of PCP. The suppression of RA disease activity may depend on concomitant/increased doses of corticosteroids for the treatment of PCP. In the present study, ETN and ABT were the most common bDMARDs used after PCP onset. In postmarketing studies of each bDMARD in patients with RA, PCP was complicated in 0.44% of patients for IFX [15], 0.18% for ETN [16], 0.3% for ADA [17], 0.2% for TCZ [18], and 0.1% for ABT [19], respectively. Although a direct comparison is not possible due to differences in patient backgrounds in each study, ETN and ABT may be associated with a lower prevalence of PCP than other bDMARDs. Therefore, the ETN and ABT may have been selected after the PCP merger. In addition, ETN is a soluble receptor preparation and has been reported to have lower antibody and complement-dependent cellular cytotoxicity against cells expressing membrane-type tumor necrosis factor (TNF) than TNF antibody preparations, suggesting that it may reduce the risk of cell-mediated immunosuppression [27]. In addition, ABT was associated with a lower incidence of comorbid infections than other bDMARDs, and the incidence of infections during ABT use was not different from that in patients treated with csDMARDs [28]. These findings suggest that ETN and ABT are more likely to be selected as bDMARDs after PCP.
To date, details of changes in RA disease activity after PCP onset have not been reported. In the present study, comparing each RA activity index at the time of PCP onset and 12 months later, DAS28CRP and SDAI decreased significantly, but CDAI did not change. The components of DAS28CRP and SDAI include serum CRP values, which may be affected by corticosteroids for PCP treatment. Therefore, regarding the evaluation of RA disease activity after the onset of PCP, it was suggested that it might be appropriate to use the CDAI, which does not include inflammatory reactions as components. As these clinical measures alone may not be sufficient to assess RA disease activity after PCP complications, a combination of objective measures, such as joint ultrasonography, may be useful.
As this was a multicenter cohort study, there were some limitations in the clinical data extraction and interpretation of the results. First, this study was a retrospective cohort study with a small sample size, and there was a possibility of bias due to missing values regarding various data. Second, because PCP was diagnosed by each attending physician at many facilities, the details of the diagnosis and severity of PCP could not be extracted. Third, all of the research participants were Japanese, and it may not be possible to generalize the results to other races. Fourth, the survivor group was skewed, with five times as many patients as non-survivors, which could confound the results. To resolve these limitations, further studies with more races and more cases are needed in the future.
4. Materials and Methods
4.1. Patients
The Kansai Consortium for Well-being of Rheumatic Disease Patients (ANSWER) cohort is a multicenter observational registry of patients with RA in the Kansai district of Japan [29,30,31]. Data from patients at seven institutes (Kyoto University, Osaka University, Osaka Medical and Pharmaceutical University, Kansai Medical University, Kobe University, Nara Medical University, and Osaka Red Cross Hospital) were included. From August 2008 to October 2017, 6939 patients with RA were registered, and 78,256 serial disease activities were available from the database. Data regarding patients with RA-complicated PCP were retrospectively collected. RA was diagnosed based on either the 1987 RA classification criteria of the American College of Rheumatology (ACR) [32] or the 2010 ACR/European League Against Rheumatism criteria [33]. Attending rheumatologists administered the treatments.
4.2. Ethics Approval and Consent to Participate
The representative facility of this registry was Kyoto University, and this observational study was conducted in accordance with the Declaration of Helsinki with the approval of the ethics committees of the following seven institutes: Kyoto University (2016-03-24/approval no. R053), Osaka University (2015-11-04/approval no. 15300), Osaka Medical and Pharmaceutical University (2014-07-14/approval no. 1529), Kansai Medical University (2017-11-21/approval no. 2014625), Kobe University (2015-03-20/approval no. 1738), Nara Medical University (2018-01-23/approval no. 1692), and the Osaka Red Cross Hospital (2015-09-01/approval no. 644). At institutes other than Osaka University Hospital, written informed consent was obtained from the participants. The Osaka University Hospital Ethics Committee board waived the requirement for patient informed consent because of the anonymous nature of the data.
4.3. PCP Diagnosis
PCP was diagnosed by the attending physicians based on the clinical and laboratory findings. In the present study, PCP was suspected when a patient had the following clinical symptoms: fever, non-productive cough, dyspnea on exertion, relatively homogenous ground glass opacity in the bilateral lung fields on chest images, elevated serum (1-3)-β-D-glucan (βDG), and progressive hypoxia. PCP was diagnosed as positive for Pneumocystis jirovecii in the sputum or bronchoalveolar lavage fluid (BALF) by polymerase chain reaction (PCR) or microscopic examination [34]. A PCR method targeting the 5.8S rRNA gene and internal transcribed spacer 2 (ITS2) gene is used to detect P. jirovecii DNA.
4.4. Data Collection
Data were extracted from the patients’ medical records. In the baseline demographic data, age, sex, duration of RA, complications, and outcomes were extracted. Laboratory findings included white blood cell (WBC) and lymphocyte counts, serum albumin, creatinine, lactate dehydrogenase (LD), C-reactive protein (CRP), Krebs von den lungen 6 (KL-6), immunoglobulin G (IgG), and serum βDG levels. The respiratory conditions, including duration of respiratory symptoms and PaO2/FiO2 ratio at baseline, were also extracted. In addition, the disease activities of RA, treatment modalities for RA, prophylaxis, and treatment modalities for PCP were also extracted at baseline, at 6 and 12 months after treatment.
4.5. Evaluation of RA Disease Activity
Data regarding swelling joints, tender joints, the patient’s global assessment of disease activity using a visual analog scale (Pt-VAS), the physician’s global assessment of disease activity via a visual analog scale (Ph-VAS), and serum CRP levels were extracted as parameters related to RA disease activity. Data regarding the Disease Activity Score-28-CRP (DAS28-CRP), the Simplified Disease Activity Index (SDAI), the Clinical Disease Activity Index (CDAI) for RA disease activity, and the Health Assessment Questionnaire (HAQ) were also extracted [35,36,37]. The DAS28-CRP is widely used, and cut-off points of 2.3, 2.7, and 4.1 have been proposed to be indicative of remission, low disease activity, and high disease activity, respectively. With DAS28-CRP, it is possible to objectively evaluate the extent of the current medical condition and to evaluate the effect of treatment by tracking numerical values over time. The SDAI is a simpler evaluation method than the DAS28-CRP and is calculated based on the number of tender and swollen joints, the Pt-VAS, the Ph-VAS, and serum CRP levels. Moreover, the CDAI is the only composite index that does not incorporate serum CRP levels and therefore can be used to conduct a disease activity evaluation essentially anytime and anywhere. HAQ is an assessment method that evaluates comprehensive quality of life, including not only the patient’s own physical function, but also mental function, various complaints, malaise, and work conditions.
4.6. Statistical Analysis
Data are presented as the median (interquartile range). Fisher’s exact test was used to compare categorical variables, and the Mann–Whitney U test was used to compare median values. The Wilcoxon signed-rank test was used to compare various pre- and post-treatment parameters. We compared the demographic and background characteristics between the two groups using univariate analysis, then estimated the hazard ratios of patient outcomes in univariate and multivariate analyses using a Cox regression model. Statistical significance was set at p < 0.05. Data were analyzed using JMP version 14.0 (SAS Institute Inc., Cary, NC, USA).
5. Conclusions
In this multicenter cohort study of Japanese patients with RA, the concomitant rate of PCP preventive drugs was low in patients with PCP, and a high dose of corticosteroids may have a poor prognosis for mortality. It is necessary to select patients with RA who require PCP prevention and to establish preventive administration methods in the future.
Author Contributions
K.N. and T.K. designed the study; H.S., K.N. and T.K. analyzed the data; H.S. and T.K. wrote the manuscript; and T.K., K.H., A.O., K.M., T.H., K.E. and T.T. revised the manuscript. All authors contributed to the collection of data. All authors have read and agreed to the published version of the manuscript.
Funding
This study reported in this publication used the ANSWER Cohort, supported by grants from 11 pharmaceutical companies (AbbVie GK, Asahi Kasei, Ayumi, Chugai, Eisai, Eli Lilly Japan K.K, Janssen K.K, Ono, Sanofi K.K, Teijin Healthcare, and UCB Japan) and an information technology services company (CAC). This was an investigator-initiated study. These companies had no roles in the study design, data collection, data analysis, data interpretation, or writing of the report.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committees of the institutions participating in the ANSWER cohort.
Informed Consent Statement
At institutes other than Osaka University Hospital, informed consent was obtained from all subjects involved in the study. The Osaka University Hospital Ethics Committee board waived the requirement for patient informed consent because of the anonymous nature of the data.
Data Availability Statement
Regarding the submission of raw data, because it is difficult to protect personal information, information will be disclosed only for reasonable offers. If any individual wants to request the data from this study, the contact should be the corresponding author.
Acknowledgments
We thank the medical staff at all the institutions who participated in the ANSWER cohort for providing the data.
Conflicts of Interest
H.S., T.K., K.H., A.Y., Y.H., Y.W., H.M. and T.T. are affiliated with a department that is financially supported by six pharmaceutical companies (Mitsubishi-Tanabe, Asahi-Kasei, Abbvie, Chugai, Eisai, and Takeda). H.S. has received payments for lectures from Pfizer, Mitsubishi-Tanabe, Asahi-Kasei, Abbvie, Eisai, Chugai, Janssen, Sanofi, UCB Japan, GlaxoSmithKline K.K., and Astellas Pharma Inc. T.K. has received payments for lectures from Abbvie, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Pfizer, and Boehringer Ingelheim. K.N. has received payments for lectures from Eisai, Eli Lilly, Asahi-Kasei, and Mitsubishi-Tanabe. K.H. has received payments for lectures from Abbvie, Asahi-Kasei, Chugai, Janssen, Mitsubishi-Tanabe, and Eisai. Y.H. has received payments for lectures from Bristol-Myers Squibb, Eli Lilly, Pfizer, Asahi-Kasei, UCBjapan, GlaxoSmithKline K.K., and Astellas Pharma Inc. Y.H. has received payments for lectures from Bristol-Myers Squibb, Eli Lilly, Pfizer, Asahi-Kasei, UCBjapan, GlaxoSmithKline K.K., and Astellas Pharma Inc. A.O. reports grants from Pfizer Inc., Bristol-Myers Squibb., and Advantest; personal fees from Asahi Kasei Pharma, Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Limited, and Daiichi Sankyo Co. Ltd. A.O. belong to the department that is financially supported by five pharmaceutical companies (Tanabe-Mitsubishi, Chugai, Ayumi, UCB-Japan, and Asahi-Kasei), Nagahama city and Toyooka city. The Department of Advanced Medicine for Rheumatic Diseases is supported by Nagahama City, Shiga, Japan; Toyooka City, Hyogo, Japan; and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., UCB Japan Co., Ltd., Asahi Kasei Pharma Corp., and AYUMI Pharmaceutical Co.). This study was initiated and conducted by the principal investigator. The stated companies had no role in the study design, data collection or analysis, manuscript writing, or the decision to submit the manuscript for publication. K.M. received speaking and/or consulting fees from AbbVie GK, Eisai Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Bristol-Myers Squibb, Daiichi Sankyo Co., Ltd., and Asahi Kasei Pharma Corp. Y.S. has received payments for lectures from Bristol-Myers Squibb, Chugai, Janssen, Eisai, and Abbvie. R.H. has received payments for lectures from Abbvie and Eisai. T.H. received a speaker fee from Asahi-Kasei, Astellas, Mitsubishi-Tanabe, and Teijin. K.E. is affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, which is supported by Taisho. K.E. has received research grants from AbbVie, Asahi-Kasei, Eisai, Mitsubishi-Tanabe, and Teijin Pharma. K.E. has received payments for lectures from AbbVie, Amgen, Asahi-Kasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Ono Pharmaceutical, Pfizer, Sanofi, Taisho, and UCB Japan. M.H. received research grants and/or speaker fees from Abbvie, Asahi Kasei, Astellas, Ayumi, Brystol Meyers, Chugai, EA Pharma, Eisai, Daiichi Sankyo, Eli Lilly, Nihon Shinyaku, Novartis Pharma, Tanabe Mitsubishi. T.T. received research grants and/or speaker fees from Abbvie, Asahi Kasei, Astellas, Brystol-Meyers Squibb, Chugai, Eisai, Eli Lilly, Janssen pharma, Nihon Shinyaku, Mitsubishi-Tanabe, Takeda, and Pfizer. Other authors (W.Y., A.Y., Y.W., H.M., Y.U., H.A., and M.K.) do not have any conflict of interest.
Abbreviations
| ABT | abatacept |
| ADA | adalimumab |
| BUC | bucillamine |
| CDAI | clinical disease activity index |
| CRP | C-reactive protein |
| CZP | certolizumab pegol |
| DAS | disease activity score |
| ETN | etanercept |
| GLM | golimumab |
| HAQ | health assessment questionnaire |
| IFX | infliximab |
| IGU | iguratimod |
| IgG | Immunoglobulin G |
| KL-6 | krebs von den Lungen-6 |
| LDH | lactate dehydrogenase |
| LTBI | latent tuberculosis infection |
| MPDN | methylprednisolone |
| MTX | methotrexate |
| NTM | nontuberculous mycobacteriosis |
| PCP | Pneumocystis Pneumonia |
| PDN | prednisolone |
| RA | rheumatoid arthritis |
| SASP | salazosulfapyridine |
| SDAI | simplified disease activity Index |
| TAC | tacrolimus |
| TCZ | tocilizumab |
| TMP/SMX | trimethoprim/sulfamethoxazole |
| TOF | tofacitinib |
| WBC | white blood cells |
| bDMARDs | biological disease modified anti-rheumatic drugs |
| tsDMARDs | targeted synthetic disease modified anti-rheumatic drugs |
References
- Smolen, J.S.; Aletaha, D.; McInnes, I.B. Rheumatoid arthritis. Lancet 2016, 388, 2023–2038. [Google Scholar] [CrossRef] [PubMed]
- Jeffrey, A.S. Rheumatoid Arthritis. Ann. Intern. Med. 2019, 170, ITC1–ITC16. [Google Scholar]
- Hashimoto, A.; Suto, S.; Horie, K.; Fukuda, H.; Nogi, S.; Iwata, K.; Tsuno, H.; Ogihara, H.; Kawakami, M.; Komiya, A.; et al. Incidence and Risk Factors for Infections Requiring Hospitalization, Including Pneumocystis Pneumonia, in Japanese Patients with Rheumatoid Arthritis. Int. J. Rheumatol. 2017, 2017, 6730812. [Google Scholar] [CrossRef] [PubMed]
- Nakajima, A.; Saito, K.; Kojima, T.; Amano, K.; Yoshio, T.; Fukuda, W.; Inoue, E.; Taniguchi, A.; Momohara, S.; Minota, S.; et al. No increased mortality in patients with rheumatoid arthritis treated with biologics: Results from the biologics register of six rheumatology institutes in Japan. Mod. Rheumatol. 2013, 23, 945–952. [Google Scholar] [CrossRef] [PubMed]
- Weyant, R.B.; Kabbani, D.; Doucette, K.; Lau, C.; Cervera, C. Pneumocystis jirovecii: A review with a focus on prevention and treatment. Expert Opin. Pharmacother. 2021, 22, 1579–1592. [Google Scholar] [CrossRef]
- Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: The PERCH multi-country case-control study. Lancet 2019, 394, 757–779. [Google Scholar] [CrossRef]
- Rekhtman, S.; Strunk, A.; Garg, A. Incidence of pneumocystosis among patients exposed to immunosuppression. J. Am. Acad. Dermatol. 2019, 80, 1602–1607. [Google Scholar] [CrossRef]
- Mori, S.; Sugimoto, M. Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations. Clin. Med. Insights Circ. Respir. Pulm. Med. 2015, 6, 29–40. [Google Scholar]
- Cohen, S.; Curtis, J.R.; DeMasi, R.; Chen, Y.; Fan, H.; Soonasra, A.; Fleischmann, R. Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis. Rheumatol. Ther. 2018, 5, 283–291. [Google Scholar] [CrossRef]
- Katsuyama, T.; Saito, K.; Kubo, S.; Nawata, M.; Tanaka, Y. Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Res. Ther. 2014, 16, R43. [Google Scholar] [CrossRef]
- Harigai, M.; Koike, R.; Miyasaka, N. Pneumocystis pneumonia associated with infliximab in Japan. N. Engl. J. Med. 2007, 357, 1874–1876. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, M.; Sakai, R.; Koike, R.; Komano, Y.; Nanki, T.; Sakai, F.; Sugiyama, H.; Matsushima, H.; Kojima, T.; Ohta, S.; et al. Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: A retrospective review of 15 cases and analysis of risk factors. Mod. Rheumatol. 2012, 22, 849–858. [Google Scholar] [CrossRef] [PubMed]
- Komano, Y.; Harigai, M.; Koike, R.; Sugiyama, H.; Ogawa, J.; Saito, K.; Sekiguchi, N.; Inoo, M.; Onishi, I.; Ohashi, H.; et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: A retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009, 61, 305–312. [Google Scholar] [CrossRef] [PubMed]
- Fuji, S.; Byrne, M.; Nagler, A.; Mohty, M.; Savani, B.N. How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021, 56, 1248–1256. [Google Scholar] [CrossRef] [PubMed]
- Takeuchi, T.; Tatsuki, Y.; Nogami, Y.; Ishiguro, N.; Tanaka, Y.; Yamanaka, H.; Kamatani, N.; Harigai, M.; Ryu, J.; Inoue, K.; et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann. Rheum. Dis. 2008, 67, 189–194. [Google Scholar] [CrossRef] [PubMed]
- Koike, T.; Harigai, M.; Inokuma, S.; Inoue, K.; Ishiguro, N.; Ryu, J.; Takeuchi, T.; Tanaka, Y.; Yamanaka, H.; Fujii, K.; et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J. Rheumatol. 2009, 36, 898–906. [Google Scholar] [CrossRef]
- Koike, T.; Harigai, M.; Ishiguro, N.; Inokuma, S.; Takei, S.; Takeuchi, T.; Yamanaka, H.; Tanaka, Y. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of the first 3000 patients. Mod. Rheumatol. 2012, 22, 498–508. [Google Scholar] [CrossRef]
- Koike, T.; Harigai, M.; Inokuma, S.; Ishiguro, N.; Ryu, J.; Takeuchi, T.; Takei, S.; Tanaka, Y.; Sano, Y.; Yaguramaki, H.; et al. Effectiveness and safety of tocilizumab: Postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J. Rheumatol. 2014, 41, 15–23. [Google Scholar] [CrossRef]
- Harigai, M.; Ishiguro, N.; Inokuma, S.; Mimori, T.; Ryu, J.; Takei, S.; Takeuchi, T.; Tanaka, Y.; Takasaki, Y.; Yamanaka, H.; et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod. Rheumatol. 2016, 26, 491–498. [Google Scholar] [CrossRef]
- Jinno, S.; Akashi, K.; Onishi, A.; Nose, Y.; Yamashita, M.; Saegusa, J. Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids. Rheumatol. Int. 2022, 42, 1403–1409. [Google Scholar] [CrossRef]
- Farr, R.W. Pneumocystis carinii pneumonia due to corticosteroids. South Med. J. 1992, 85, 52–53. [Google Scholar] [CrossRef] [PubMed]
- Msaad, S.; Yangui, I.; Bahloul, N.; Abid, N.; Koubaa, M.; Hentati, Y.; Ben Jemaa, M.; Kammoun, S. Do inhaled corticosteroids increase the risk of Pneumocystis pneumonia in people with lung cancer? World J. Clin. Cases 2015, 16, 843–847. [Google Scholar] [CrossRef] [PubMed]
- Lang, Q.; Li, L.; Zhang, Y.; He, X.; Liu, Y.; Liu, Z.; Yan, H. Development and Validation of a Diagnostic Nomogram for Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Pneumonia Patients Undergoing Oral Glucocorticoid Treatment. Infect. Drug Resist. 2023, 16, 755–767. [Google Scholar] [CrossRef]
- Alsayed, A.R.; Talib, W.; Al-Dulaimi, A.; Daoud, S.; Al Maqbali, M. The first detection of Pneumocystis jirovecii in asthmatic patients post-COVID-19 in Jordan. Bosn. J. Basic Med. Sci. 2022, 22, 784–790. [Google Scholar]
- Gentile, I.; Viceconte, G.; Lanzardo, A.; Zotta, I.; Zappulo, E.; Pinchera, B.; Scotto, R.; Schiano, M.N.; Foggia, M.; Giaccone, A.; et al. Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience. Int. J. Environ. Res. Public Health 2021, 18, 11399. [Google Scholar] [CrossRef] [PubMed]
- Alsayed, A.R.; Al-Dulaimi, A.; Alkhatib, M.; Al Maqbali, M.; Al-Najjar, M.A.A.; Al-Rshaidat, M.M.D. A comprehensive clinical guide for Pneumocystis jirovecii pneumonia: A missing therapeutic target in HIV-uninfected patients. Expert Rev. Respir. Med. 2022, 16, 1167–1190. [Google Scholar] [CrossRef]
- Arora, T.; Padaki, R.; Liu, L.; Hamburger, A.E.; Ellison, A.R.; Stevens, S.R.; Louie, J.S.; Kohno, T. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009, 45, 124–131. [Google Scholar] [CrossRef]
- Ozen, G.; Pedro, S.; Schumacher, R.; Simon, T.A.; Michaud, K. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: Data from an observational study. Arthritis Res. Ther. 2019, 21, 141. [Google Scholar] [CrossRef]
- Hashimoto, M.; Furu, M.; Yamamoto, W.; Fujimura, T.; Hara, R.; Katayama, M.; Ohnishi, A.; Akashi, K.; Yoshida, S.; Nagai, K.; et al. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: The ANSWER cohort study. Arthritis Res. Ther. 2018, 20, 165. [Google Scholar] [CrossRef]
- Ebina, K.; Hashimoto, M.; Yamamoto, W.; Ohnishi, A.; Kabata, D.; Hirano, T.; Hara, R.; Katayama, M.; Yoshida, S.; Nagai, K.; et al. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis—The ANSWER cohort study. PLoS ONE 2018, 13, e0194130. [Google Scholar] [CrossRef]
- Ebina, K.; Hashimoto, M.; Yamamoto, W.; Hirano, T.; Hara, R.; Katayama, M.; Onishi, A.; Nagai, K.; Son, Y.; Amuro, H.; et al. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—The ANSWER cohort study. Arthritis Res. Ther. 2019, 21, 91. [Google Scholar] [CrossRef]
- Arnett, F.C.; Edworthy, S.M.; Bloch, D.A.; McShane, D.J.; Fries, J.F.; Cooper, N.S.; Healey, L.A.; Kaplan, S.R.; Liang, M.H.; Luthra, H.S.; et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31, 315–324. [Google Scholar] [CrossRef] [PubMed]
- Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O., 3rd; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62, 2569–2581. [Google Scholar] [CrossRef]
- Bateman, M.; Oladele, R.; Kolls, J.K. Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches. Med. Mycol. 2020, 58, 1015–1028. [Google Scholar] [CrossRef] [PubMed]
- van Riel, P.L.; Renskers, L. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin. Exp. Rheumatol. 2016, 34, S40–S44. [Google Scholar] [PubMed]
- Smolen, J.S.; Aletaha, D. Scores for all seasons: SDAI and CDAI. Clin. Exp. Rheumatol. 2014, 32, S75–S79. [Google Scholar]
- Anderson, J.K.; Zimmerman, L.; Caplan, L.; Michaud, K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res. 2011, 63, S14–S36. [Google Scholar]
Table 1.
Characteristics of the subjects at baseline.
| Characteristics | All Patients (n = 37) |
|---|---|
| Age (years) | 69 (63–75) |
| Female, number (%) | 27 (73.0) |
| Disease duration (years) | 10.7 (2.77–20.4) |
| Missing or unmeasurable | 1 |
| DAS28CRP | 3.58 (2.92–4.57) |
| Missing or unmeasurable | 18 |
| CDAI | 8.6 (2–12.2) |
| Missing or unmeasurable | 20 |
| SDAI | 16.1 (7.44–22.5) |
| Missing or unmeasurable | 20 |
| HAQ score | 0.81 (0–1.78) |
| Missing or unmeasurable | 23 |
| Laboratory findings | |
| WBC (/μL) | 7900 (5960–10,255) |
| Lymphocytes (/μL) | 800 (550–1476) |
| Serum alubmin (mg/dL) | 3.2 (2.75–3.5) |
| Serum creatinine (mg/dL) | 0.80 (0.63–1.02) |
| Serum LDH (IU/L) | 390 (289.5–504) |
| Serum CRP (mg/dL) | 6.823 (2.83–11.7) |
| Missing or unmeasurable | 1 |
| Serum KL-6 (U/mL) | 556 (391–1032) |
| Missing or unmeasurable | 4 |
| Serum IgG (mg/dL) | 948 (797–1145) |
| Missing or unmeasurable | 10 |
| Serum β-D-glucan (pg/mL) | 34.8 (22.9–123.1) |
| Missing or unmeasurable | 3 |
| Treatments | |
| MTX use, number (%) | 32 (86.5) |
| MTX dose (mg/week) | 7 (4–9.5) |
| Missing or unmeasurable | 1 |
| PDN use, number (%) | 25 (67.6) |
| PDN dose (mg/day) | 4 (0–9) |
| Duration of PDN use (weeks) | 16 (0–287) |
| Missing or unmeasurable | 15 |
| TAC/SASP/BUC/IGU use, number | 4/2/6/6 |
| IFX/ETN/GLM/TCZ/ABT use, number | 2/2/1/4/3 |
| TOF use, number | 2 |
| Comorbidities | |
| Diabetes mellitus, number (%) | 8 (21.6) |
| Intistitial lung disease, number (%) | 11 (29.7) |
| Emphysema, number (%) | 4 (10.8) |
| Bronchiectasis, number (%) | 3 (8.11) |
| LTBI, number (%) | 2 (5.41) |
| Lung NTM, number (%) | 1 (2.70) |
| Chemical prophylaxis | |
| SMX/TMP mixture, number (%) | 0 (0) |
| Atovaquone, number (%) | 3 (8.11) |
| Pentamidine, number (%) | 0 (0) |
Values indicate the median (interquartile range) unless otherwise mentioned.
Table 2.
Treatments for PCP.
| TMP/SMX mixture use, number (%) | 35 (94.6) |
| Baseline TMP/SMX mixture dose (g/day) | 9 (9–12) |
| Missing or unmeasurable | 2 |
| Pentamidine use, number (%) | 12 (32.4) |
| Atovaquone use, number (%) | 5 (13.5) |
| MPDN pulse therapy use, number (%) | 12 (32.4) |
| PDN use, number (%) | 35 (94.3) |
| Missing or unmeasurable | 2 |
| Baseline PDN dose (mg/day) | 64 (40–80) |
| Missing or unmeasurable | 2 |
Values indicate the median (interquartile range) unless otherwise mentioned.
Table 3.
Clinical characteristics at baseline between PCP death patients and survival patients.
| Characteristics | Death (n = 6) | Survivors (n = 31) | p Value |
|---|---|---|---|
| Age (years) | 65.5 (59–73.5) | 69 (63–75) | 0.375 |
| Female, number (%) | 3 (50) | 24 (77.42) | 0.166 |
| Disease duration (years) | 7.67 (0.92–15.4) | 10.8 (2.83–21.3) | 0.314 |
| Missing or unmeasurable | 1 | ||
| Stage 1/2/3/4, number | (2/3/0/1) | (7/5/2/15) | 0.236 |
| Class I/II/III/IV, number | (0/5/1/0) | (7/17/4/1) | 0.539 |
| DAS28CRP | 3.56 (3.55–4.29) | 3.83 (2.73–4.62) | 0.955 |
| Missing or unmeasurable | 3 | 15 | |
| CDAI | 8.6 (5.7–12.5) | 8.55 (1.93–13.1) | 0.85 |
| Missing or unmeasurable | 3 | 17 | |
| SDAI | 23.5 (5.70–24.5) | 14.4 (8.13–19.8) | 0.488 |
| Missing or unmeasurable | 3 | 17 | |
| HAQ | 1.88 (0.38–2.15) | 0.75 (0–1) | 0.237 |
| Missing or unmeasurable | 3 | 20 | |
| Laboratory findings | |||
| WBC (/μL) | 9400 (4738–11,400) | 7840 (5960–9800) | 0.636 |
| Lymphocytes (/μL) | 950 (170–1716) | 800 (580–1400) | 0.757 |
| Serum Alubmin (mg/dL) | 2.75 (2.53–3.45) | 3.3 (3–3.5) | 0.238 |
| Serum creatinine (mg/dL) | 0.79 (0.66–2.63) | 0.8 (0.59–0.97) | 0.578 |
| Serum LDH (IU/L) | 455 (307–709) | 360 (287–504) | 0.293 |
| Serum CRP (mg/dL) | 15.9 (6.98–18.6) | 5.7 (1.85–9.56) | 0.035 |
| Missing or unmeasurable | 1 | ||
| Serum KL-6 (U/mL) | 954 (529–1724) | 499 (354–916) | 0.118 |
| Missing or unmeasurable | 4 | ||
| Serum IgG (mg/dL) | 874 (480–1249) | 961 (797–1127) | 0.671 |
| Missing or unmeasurable | 3 | 7 | |
| Serum β-D-glucan (pg/mL) | 77.8 (15.6–1626) | 34.8 (23.2–77.0) | 0.603 |
| Missing or unmeasurable | 3 | ||
| Treatments for RA | |||
| MTX use, number (%) | 4 (66.7) | 28 (90.3) | 0.177 |
| MTX dose (mg/week) | 5 (0–7) | 8.0 (4.0–10.0) | 0.086 |
| PDN use, number (%) | 6 (100) | 19 (61.3) | 0.064 |
| PDN dose (mg/day) | 9 (5.75–19.4) | 3 (0–5) | 0.006 |
| Duration of PDN use (weeks) | 158 (23–377) | 12 (0–167) | 0.222 |
| Missing or unmeasurable | 2 | 13 | |
| TAC use, number (%) | 0 (0) | 4 (12.9) | 0.352 |
| SASP use, number (%) | 1 (16.7) | 1 (3.23) | 0.183 |
| bDMARDs/tsDMARDs use, number | 1 (16.7) | 13 (41.9) | 0.243 |
| Comorbidities | |||
| Diabetes mellitus, number (%) | 1 (16.7) | 7 (22.6) | 0.747 |
| Interstitial lung disease, number (%) | 1 (16.7) | 10 (32.3) | 0.444 |
| Emphysema, number (%) | 0 (0) | 4 (12.9) | 0.352 |
| Bronchiectasis, number (%) | 0 (0) | 3 (9.68) | 0.427 |
| LTBI, number (%) | 0 (0) | 2 (6.45) | 0.522 |
| Lung NTM infection, number (%) | 0 (0) | 1 (3.23) | 0.656 |
Values indicate the median (interquartile range) unless otherwise mentioned.
Table 4.
Prognostic factors of death from PCP in patients with RA.
| Univariable Analysis | Multivariable Analysis | |||||
|---|---|---|---|---|---|---|
| Risk Factors | Crude HR | 95% CI | p | Adjusted HR | 95% CI | p |
| Age | 0.978 | 0.908–1.076 | 0.611 | 0.93 | 0.839–1.050 | 0.213 |
| Baseline serum CRP levels | 1.094 | 0.990–1.188 | 0.075 | 1.103 | 0.968–1.249 | 0.127 |
| Baseline PDN dose | 1.193 | 1.066–1.340 | 0.003 | 1.23 | 1.448–0.813 | 0.003 |
The hazard ratios of death due to PCP were derived from univariable and multivariable Cox regression analysis. HR, hazard ratio; CI, confidence interval.
Table 5.
Changes in treatment modalities for RA and chemical prophylaxis for PCP during the course after PCP treatment.
Table 5.
Changes in treatment modalities for RA and chemical prophylaxis for PCP during the course after PCP treatment.
| Baseline (n = 37) | 6 Months after (n = 24) | 12 Months after (n = 21) | p Value (Initial vs. 6 months) | p Value (Initial vs. 12 Months) | p Value (6 Months vs. 12 Months) | |
|---|---|---|---|---|---|---|
| Treatment modalities for RA | ||||||
| MTX use, number (%) | 32 (86.5) | 12 (50) | 10 (47.6) | 0.002 | 0.002 | 0.317 |
| MTX dose (mg/week) | 7 (4–9.5) | 1 (0–7.5) | 1 (0–7) | <0.001 | <0.001 | 0.471 |
| PDN use, number (%) | 25 (67.6) | 20 (83.3) | 15 (71.4) | 0.011 | 0.096 | 0.157 |
| PDN dose (mg/day) | 4 (0–9) | 5 (2–7.38) | 5 (0–7) | 0.856 | 0.814 | 0.035 |
| bDMARDs/tsDMARDs use, number (%) | 14 (37.8) | 5 (20.8) | 7 (33.3) | 0.014 | 0.317 | 0.157 |
| Modalities of bDMARDs/tsDMARDs | IFX 2, ETN 2, TCZ 4, GLM 1, ABT 3, TOF 2 | ETN 1, ABT 4 | ETN 2, ABT 4, TCZ 1 | - | - | - |
| Chemical prophylaxis for PCP | ||||||
| TMP/SMX mixture use, number (%) | 0 (0) | 14 (58.3) | 12 (57.1) | <0.001 | <0.001 | 1 |
| TMP/SMX mixture dose (mg/week) | 0 (0) | 2.5 (0–7) | 3 (0–7) | <0.001 | <0.001 | 0.712 |
| Atovaquone use, number (%) | 3 (8.1) | 3 (12.5) | 1 (4.76) | 1 | 0.317 | 0.317 |
Values indicate the median (interquartile range) unless otherwise mentioned.
Table 6.
Changes in disease activities of RA during the course after PCP treatment.
| Baseline (n = 37) | 6 Months after | 12 Months after | p Value (Initial vs. 6 Months) | p Value (Initial vs. 12 Months) | p Value (6 Months vs. 12 Months) | |
|---|---|---|---|---|---|---|
| DAS28CRP | 3.58 (2.92–4.57) | 2.48 (1.85–3.90) | 1.91 (1.75–2.47) | 0.046 | 0.001 | 0.271 |
| Missing or unmeasurable | 18 | 21 | 23 | |||
| CDAI | 8.6 (2–12.15) | 7.4 (1–9) | 3 (2.1–8.8) | 0.359 | 0.074 | 0.182 |
| Missing or unmeasurable | 20 | 22 | 24 | |||
| SDAI | 16.05 (7.44–22.45) | 7.4 (1.85–12.5) | 3.3 (2.62–8.88) | 0.188 | 0.012 | 0.285 |
| Missing or unmeasurable | 20 | 22 | 24 | |||
| CRP | 6.83 (2.83–11.66) | 0.26 (0.12–2.58) | 0.18 (0.05–1.71) | <0.001 | <0.001 | 0.098 |
| Missing or unmeasurable | 1 | 13 | 18 |
Values indicate the median (inter quartile range) unless otherwise mentioned.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Shiba, H.; Kotani, T.; Nagai, K.; Hata, K.; Yamamoto, W.; Yoshikawa, A.; Wada, Y.; Hiramatsu, Y.; Makino, H.; Ueda, Y.; et al. Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study. Int. J. Mol. Sci. 2023, 24, 7399. https://doi.org/10.3390/ijms24087399
AMA Style
Shiba H, Kotani T, Nagai K, Hata K, Yamamoto W, Yoshikawa A, Wada Y, Hiramatsu Y, Makino H, Ueda Y, et al. Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study. International Journal of Molecular Sciences. 2023; 24(8):7399. https://doi.org/10.3390/ijms24087399
Chicago/Turabian StyleShiba, Hideyuki, Takuya Kotani, Koji Nagai, Kenichiro Hata, Wataru Yamamoto, Ayaka Yoshikawa, Yumiko Wada, Yuri Hiramatsu, Hidehiko Makino, Yo Ueda, and et al. 2023. "Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study" International Journal of Molecular Sciences 24, no. 8: 7399. https://doi.org/10.3390/ijms24087399
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
